Analysts Initiate Coverage on Everus and Nuvation Bio Stocks

DA Davidson has initiated coverage on Everus stock with a 'buy' rating, citing M&A growth potential, while Cantor Fitzgerald has started coverage on Nuvation Bio stock with an 'overweight' rating. These initiations reflect analyst confidence in the future performance of these companies.